The Asp40 μ-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers [17]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 1, 2007, Pages 112-114

  Mitchell, Jennifer M ^a,b,c   Fields, Howard L ^a,b,c   White, Raymond L ^a,c   Meadoff, Thomas M ^a   Joslyn, Geoff ^c   Rowbotham, Michael C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; MU OPIATE RECEPTOR; NALTREXONE; RIBOFLAVIN;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ALLELE; AMINO ACID SUBSTITUTION; ANXIETY; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LETTER; MALE; MOTIVATION; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOLOGICAL RATING SCALE; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; THERAPY EFFECT; URINALYSIS; VOMITING;

ADULT; ALCOHOLISM; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

EID: 33846229594     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31802e68b0     Document Type: Letter

References (22)

1. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-593.
2. O'Malley SS, Krishnan-Sarin S, Farren C, et al. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology. 2002;160:19-29.
3. Drobes DJ, Anton RF, Thomas SE, et al. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003;28:755-764.
4. Bergen AW, Kokoszka J, Peterson JR, et al. Mu-opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry. 1997;2:490-494.
5. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human Mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95:9608-9613.
6. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the Mu opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546-1552.
7. Hernandez-Avila CA, Wand G, Luo X, et al. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet. 2003;118:60-65.
8. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83:262-268.
9. Merikangas KR, Gelernter CS. Comorbidity for alcoholism and depression. Psychiatr Clin North Am. 1990;13:613-632.
10. Anisman H, Merali Z. Understanding stress: characteristics and caveats. Alcohol Res Health. 1999;23:241-249.
11. Govoni S, Pasinetti G, Bianchi A, et al. Heavy drinking decreases plasma met-enkephalin concentrations. Alcohol Drug Res. 1987;7:93-98.
12. Aguirre JC, Del Arbol JL, Raya J, et al. Plasma beta-endorphin levels in chronic alcoholics. Alcohol. 1990;7:409-412.
13. Chong RY, Oswald L, Yang X, et al. The muopioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology. 2006;31:204-211.
14. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales (DASS). Psychology Foundation Monograph. New South Wales, Australia; 1993.
15. Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption - II. Addiction. 1993;88:791-804.
16. Kellogg SH, McHugh PF, Bell K, et al. The Kreek-McHugh-Schluger-Kellogg Scale: a new, rapid method for quantifying substance abuse and its possible applications. Drug Alcohol Depend. 2003;69:137-150.
17. Wright NR, Cameron D. The influence of habitual alcohol intake on breath-alcohol concentrations following prolonged drinking. Alcohol Alcohol. 1998;33:495-501.
18. Townshend JM, Duka T. Patterns of alcohol drinking in a population of young social drinkers: a comparison of questionnaire and diary measures. Alcohol Alcohol. 2002;37:187-192.
19. Sellers EM, Kadlec KE, Kaplan HL, et al. Limitations in the measurement of urine ethanol in clinical trials to monitor ethanol consumption. J Stud Alcohol. 1998;49:567-570.
20. Beyer A, Koch T, Schroder H, et al. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem. 2004;89:553-560.
21. Zhang Y, Wang D, Johnson AD, et al. Allelic expression imbalance of human Mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280:32618-32624.
22. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000;25:195-200.